Oct. 31 Quick Takes: KKR, OMX-backed Replay introduces eye-focused Eudora
Plus: China excludes GSK’s Avodart, affecting £300K in sales and updates from Inventiva, Instil, Actinium and more
Three months after launching with $55 million in seed capital from KKR and OMX Ventures, hub-and-spoke company Replay Holdings LLC has introduced the first of four planned product-focused entities: Eudora Therapeutics, which will develop gene therapies using HSV vectors to treat retinal disorders. Co-founder Lachlan MacKinnon told BioCentury in July that Replay intends to “separate technology development from product development” via its model; additional product companies will address disorders of the brain, skin and muscle.
China has excluded Avodart dutasteride from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) from the country’s volume-based procurement program as a result of a “review of manufacturing processes following an inspection of our contract manufacturer,” a company spokesperson told BioCentury. The decision affects about £300,000 in sales, less than 1% of GSK’s overall 2022 sales to China...